Comprehensive Monograph on Lithium Carbonate (DB14509): A Foundational Agent in Modern Psychopharmacology

I. Introduction: An Enduring Legacy in Psychiatry

Overview

Lithium carbonate, a simple inorganic salt, occupies a unique and revered position in the history of medicine. Far more than a mere chemical compound, it represents a paradigm shift in the biological treatment of mental illness. For over half a century, it has been regarded as the "gold standard" for the management of bipolar disorder, a designation it retains despite the emergence of newer, more profitable, and often more aggressively marketed therapeutic agents.[1] The story of lithium is one of profound paradox: its remarkable and specific efficacy in stabilizing mood is juxtaposed with a narrow therapeutic window, a demanding monitoring protocol, and a significant potential for toxicity. This fundamental tension between benefit and risk defines the clinical experience with lithium and underscores the necessity of expert knowledge for its safe and effective use. Its discovery ushered in the era of modern psychopharmacology, and its continued study reveals new potential, ensuring its enduring relevance.[3]

Historical Trajectory

The therapeutic use of lithium predates modern medicine by millennia. Ancient Roman physicians, without understanding the underlying chemistry, would direct patients with "nervous and temperamental" dispositions to bathe in specific mineral springs across Europe, which are now known to possess the continent's highest natural concentrations of lithium salts.[3]

The scientific journey began in the mid-19th century. In 1847, London internist Alfred Baring Garrod identified uric acid in the blood of his patients with gout and subsequently investigated lithium salts as a potential solvent for these crystals.[1] He hypothesized that an excess of uric acid could affect the central nervous system, a condition he termed "brain gout," which he associated with depression.[2] This led to the use of lithium for a range of ailments, and by the 1870s, prominent physicians like Silas Weir Mitchell and William Hammond in the United States were recommending lithium bromide for mania, nervousness, and as a hypnotic.[1]

The modern era of lithium therapy, however, was launched by the serendipitous and seminal work of Australian psychiatrist John Cade in 1949.[1] Working in a small repatriation hospital, Cade hypothesized that mania was caused by a circulating toxin that could be identified in patients' urine. To test this, he injected urine from manic, schizophrenic, and depressed patients into guinea pigs. To make the uric acid in the urine more soluble for injection, he used lithium urate, the most soluble urate salt. He observed that the lithium itself had a profound calming effect on the guinea pigs, rendering them placid and unresponsive to stimuli. Recognizing the significance of this accidental finding, he administered lithium citrate and carbonate to ten patients with mania, observing dramatic and rapid improvements, a discovery that would forever change the treatment of mood disorders.[4]

Despite this breakthrough, lithium's path to widespread clinical use and regulatory approval was remarkably slow, particularly in the United States. A primary reason for this delay was economic; as a naturally occurring salt, lithium carbonate could not be patented, which provided little financial incentive for pharmaceutical companies to invest in the costly process of clinical trials and FDA submission.[3] While European countries began to approve various lithium salts in the 1960s—France in 1961, the United Kingdom in 1966, and Germany in 1967—the agent remained largely unavailable in the U.S..[1]

The tide began to turn with two key developments. First, the pioneering, placebo-controlled trials conducted by Mogens Schou in Denmark in the 1950s provided rigorous scientific evidence of lithium's efficacy in treating acute mania and preventing relapse.[1] Second, the introduction of the Coleman flame photometer in 1958 made it possible to accurately and reliably measure lithium concentrations in blood, a critical technological advance that transformed a potentially toxic substance into a manageable therapeutic agent.[1] Following the work of researchers like Samuel Gershon, who introduced lithium to North American investigators in the 1960s [1], the U.S. Food and Drug Administration (FDA) finally approved lithium carbonate for the treatment of manic episodes on April 6, 1970, making the United States the 50th country to do so.[5] Much later, on October 4, 2018, the indication was expanded to include pediatric patients aged 7 to 17, based on data from the Collaborative Lithium Trials (COLT).[11]

Chemical Identity and Formulations

Lithium carbonate is a small molecule inorganic compound identified by DrugBank ID DB14509 and CAS Number 554-13-2.[12] It is also known by synonyms such as dilithium carbonate and carbonic acid, dilithium salt.[12]

Its physicochemical properties are well-defined. It has the molecular formula Li2​CO3​ and a molecular weight of 73.89 g/mol.[12] It exists as a white, odorless, alkaline powder or monoclinic crystal.[13] It has a high melting point of 723°C and decomposes at around 1300°C.[13] Unlike other alkali metal carbonates, it is poorly soluble in water (1.31 g/100 mL at 20°C) and is insoluble in alcohol.[15] This low solubility has been exploited to develop sustained-release preparations, which slow its absorption rate from the intestine.[17]

Lithium is available for oral administration in several formulations to accommodate different clinical needs [18]:

• Immediate-Release Capsules: 150 mg, 300 mg, 600 mg
• Immediate-Release Tablets: 300 mg
• Extended-Release Tablets: 300 mg, 450 mg
• Oral Solution: 8 mEq of lithium ion per 5 mL, which is equivalent to the amount of lithium in 300 mg of lithium carbonate.[18]

Source: Wikimedia Commons. This image is in the public domain.20

---

Table 1: Physicochemical and Structural Properties of Lithium Carbonate

Property	Value / Description	Source(s)
IUPAC Name	dilithium carbonate	13
DrugBank ID	DB14509	21
CAS Number	554-13-2	12
Molecular Formula	Li2​CO3​	12
Molecular Weight	73.89 g/mol	13
Appearance	White, odorless powder; solid at 20°C	13
Melting Point	723°C	13
Boiling Point	1310°C (decomposes)	13
Solubility	Poorly soluble in water (1.3 g/100mL); insoluble in alcohol	15
SMILES	[Li+].[Li+].C(=O)([O-])[O-]	13
InChIKey	XGZVUEUWXADBQD-UHFFFAOYSA-L	13

---

II. Pharmacodynamics: Unraveling a Multifaceted Mechanism of Action

Overview of a Complex Mechanism

Despite its long and successful history in clinical practice, the precise biochemical mechanism underlying lithium's therapeutic effects remains one of the great enigmas of psychopharmacology.[22] Research has shown that lithium does not operate through a single receptor or enzyme but rather exerts its influence through a complex and pleiotropic array of actions, modulating multiple intracellular signaling pathways and neurotransmitter systems.[25] The common theme emerging from decades of study is that lithium affects numerous steps in cellular signaling, often inhibiting stimulated activities while enhancing basal functions, thereby producing a stabilizing effect on neuronal function.[25]

Primary Molecular Targets and Signaling Pathways

Two hypotheses have emerged as leading explanations for lithium's mood-stabilizing properties.

Inhibition of Glycogen Synthase Kinase-3 (GSK-3)

A central and extensively studied mechanism is lithium's ability to inhibit the enzyme glycogen synthase kinase-3 (GSK-3), particularly the GSK-3β isoform.[4] GSK-3 is a serine/threonine kinase that plays a pivotal role in a vast number of cellular processes, including energy metabolism, neurodevelopment, inflammation, and apoptosis.[26] The inhibition of this ubiquitous enzyme by lithium is thought to be a key upstream event that triggers a cascade of downstream effects. One of the most important consequences is the modulation of β-catenin, a protein regulated by GSK-3. By inhibiting GSK-3, lithium prevents the degradation of β-catenin, allowing it to accumulate and translocate to the nucleus, where it influences the expression of genes involved in cellular resilience and neuroprotection.[25] This single action provides a powerful and plausible link between lithium's mood-stabilizing effects and its increasingly recognized neuroprotective properties.[27]

Modulation of the Inositol Phosphate Pathway

Another primary hypothesis focuses on lithium's effect on the phosphatidylinositol (PI) second messenger system.[24] Lithium directly inhibits the enzyme inositol monophosphatase (IMPase) and other key enzymes in this pathway.[26] The PI system is crucial for signal transduction from a wide variety of neurotransmitter receptors, including muscarinic cholinergic and α1-adrenergic receptors. By inhibiting IMPase, lithium leads to a depletion of cellular inositol, which in turn dampens the signaling cascade of these G-protein coupled receptors. This action may effectively reduce the excessive neuronal excitability and signal transmission that are thought to characterize manic states.[24]

Effects on Neurotransmitter Systems

Beyond its effects on second messenger systems, lithium directly influences the function of several key neurotransmitter systems. Preclinical studies have shown that lithium alters sodium transport in nerve and muscle cells, a fundamental action for an alkali metal ion.[22] It also appears to promote a shift toward the intraneuronal metabolism of catecholamines, such as dopamine and norepinephrine.[22] Further theories suggest that lithium may achieve its stabilizing effects by blocking dopamine-receptor supersensitivity and enhancing the net function of inhibitory neurotransmitters like serotonin (5-HT) and γ-aminobutyric acid (GABA), while attenuating the activity of the primary excitatory neurotransmitter, glutamate.[23]

Neurotrophic and Neuroprotective Properties

One of the most exciting areas of modern lithium research is its profound effect on neuronal structure and survival. This body of evidence suggests that lithium may not just treat the symptoms of mood disorders but may also be a disease-modifying agent that protects the brain from the pathological changes associated with recurrent illness.

Structural Brain Changes

A consistent finding from neuroimaging studies is that long-term treatment with lithium is associated with structural brain changes. Patients treated with lithium often exhibit larger cortical and hippocampal volumes and an overall increase in gray matter volume compared to unmedicated patients.[6] These structural findings are corroborated by magnetic resonance spectroscopy studies, which show increased levels of N-acetyl aspartate (NAA), a marker of neuronal health and viability, in the brains of lithium-treated individuals.[6] These effects appear to be independent of lithium's ability to prevent mood episodes, suggesting a direct neurotrophic action.[25]

Molecular Mechanisms of Neuroprotection

The structural changes observed in the brain are underpinned by lithium's actions at the molecular level. Lithium has been shown to increase the activity of CREB (cAMP response element-binding protein), a critical transcription factor that regulates the expression of genes involved in neuronal survival and plasticity.[25] Key downstream targets of CREB that are upregulated by lithium include Brain-Derived Neurotrophic Factor (BDNF), a potent neurotrophin that promotes the growth and survival of neurons, and Bcl-2, a primary anti-apoptotic protein.[25] In parallel, lithium inhibits the function of several pro-apoptotic factors, including Bax, p53, and calpain.[25] This dual action—promoting pro-survival pathways while inhibiting pro-death pathways—is believed to be central to its neuroprotective effects. Collectively, these actions promote neurogenesis (the birth of new neurons), particularly in the hippocampus, and help restore brain plasticity that may be compromised by stress and recurrent mood episodes.[25]

Immunological and Hematological Effects

Lithium also exerts effects outside the central nervous system. It is known to cause a benign elevation in white blood cell counts (leukocytosis) by stimulating the production of granulocytes.[6] This effect is being investigated for its potential immunomodulatory role. There is growing evidence that bipolar disorder is associated with a state of "low-grade inflammation," and lithium's ability to modulate inflammatory cascades may contribute to its therapeutic action.[6]

The convergence of lithium's proposed mechanisms offers a compelling biological narrative. The same molecular actions, such as GSK-3β inhibition and BDNF upregulation, that are thought to stabilize mood are also central to neuroprotection. This is not merely a coincidence but likely reflects the shared biological pathways underlying mood regulation and neuronal resilience. The pathophysiology of both severe mood disorders and neurodegenerative diseases involves elements of impaired neurotrophic support, neuroinflammation, and cellular stress. By targeting these fundamental processes, lithium appears to function as both a mood stabilizer and a neuroprotective agent. This reframes the drug from a simple "antimanic" to a potentially "disease-modifying" agent in psychiatry, capable of not only managing acute symptoms but also protecting the brain from the long-term structural and functional consequences of recurrent illness.

III. Pharmacokinetics: The Clinical Implications of ADME

Overview

The clinical use of lithium carbonate is profoundly dictated by its unique pharmacokinetic profile. Its absorption, distribution, metabolism, and excretion (ADME) characteristics are not just academic details; they are the very factors that define its narrow therapeutic index, necessitate rigorous blood level monitoring, and create its specific and predictable pattern of drug interactions and toxicity risks. A thorough understanding of lithium's pharmacokinetics is therefore essential for any clinician prescribing the medication.

Absorption

Following oral administration, lithium is rapidly and completely absorbed from the gastrointestinal (GI) tract.[29] For immediate-release formulations, such as standard tablets and capsules, peak plasma concentrations (

Cmax​) are typically reached within 0.25 to 3 hours.[29] For sustained-release (SR) or extended-release (ER) formulations, which are designed to slow absorption and potentially reduce peak-dose side effects,

Cmax​ is reached later, generally between 2 and 6 hours.[29] The plasma concentration-time curve after a dose is complex and does not follow a simple one-compartment model, reflecting a slower distribution phase into tissues.[23]

Distribution

Once absorbed into the bloodstream, lithium distributes throughout the body's total water space, with an apparent volume of distribution (Vd​) of approximately 0.7 to 1.0 L/kg.[22] A key characteristic is that lithium does not bind to plasma proteins, meaning its entire circulating concentration is pharmacologically active and available for distribution and excretion.[29] There is significant inter-patient variability in the time it takes for lithium to distribute from the serum into its sites of action in the tissues.[23] This variability is a primary reason why the timing of blood draws for therapeutic monitoring must be strictly standardized.

Metabolism

The metabolic profile of lithium is one of its most defining features: lithium is not metabolized by the human body.[29] As a simple element, it is not subject to enzymatic transformation in the liver or elsewhere. It is absorbed, distributed, and excreted as the unchanged lithium ion (

Li+). This lack of metabolism means that it does not interact with the cytochrome P450 (CYP) enzyme system, which is a major advantage as it avoids the multitude of CYP-mediated drug-drug interactions that complicate the use of many other psychotropic medications.[33]

Excretion

The elimination of lithium is almost entirely dependent on the kidneys. Over 95% of an administered dose is excreted unchanged in the urine.[22] The rate of renal excretion is directly proportional to the concentration of lithium in the plasma.[22] In a healthy adult with normal renal function, the elimination half-life (

t1/2​) is approximately 24 hours, allowing for steady-state concentrations to be reached after about 5 days of consistent dosing.[22]

The most critical aspect of lithium's excretion is its handling within the nephron. After being freely filtered at the glomerulus, approximately 80% of the lithium is reabsorbed back into the bloodstream in the proximal tubules.[29] In this part of the kidney, lithium directly competes with sodium for reabsorption. This physiological competition is the mechanistic cornerstone of many of lithium's most dangerous clinical risks. Any condition that leads to sodium depletion in the body (such as dehydration, use of diuretics, or a low-salt diet) will trigger the kidneys to increase sodium reabsorption to conserve it. Because lithium is handled similarly, this compensatory mechanism also leads to increased lithium reabsorption, causing serum lithium levels to rise, potentially into the toxic range.[17]

Factors Influencing Pharmacokinetics

Several patient-specific factors can significantly alter lithium's pharmacokinetics and must be considered when dosing:

• Renal Function: This is the single most important factor. Since lithium is almost exclusively cleared by the kidneys, any degree of renal impairment will reduce its clearance, prolong its half-life, and increase the risk of accumulation and toxicity. Use is contraindicated in severe renal impairment (Creatinine Clearance [CLcr] < 30 mL/min).[17]
• Sodium and Fluid Balance: As described above, any state of sodium or volume depletion will increase lithium retention. This includes dehydration from fever, excessive sweating, or GI illness, as well as iatrogenic causes like low-sodium diets or diuretic therapy.[22]
• Age: Elderly patients typically have a lower glomerular filtration rate (GFR) and less total body water compared to younger adults. Both factors lead to reduced clearance and a smaller volume of distribution, necessitating lower starting doses and more cautious titration.[17] Conversely, children tend to have a higher clearance relative to their body weight and may require higher mg/kg doses to achieve therapeutic levels.[17]
• Body Weight: Lithium clearance is correlated with total body weight, while its volume of distribution is more closely related to ideal body weight or fat-free mass. This suggests that obese patients may require higher maintenance doses due to higher clearance, but starting doses should be based on ideal body weight.[17]
• Cardiovascular Disease: Conditions like congestive heart failure can decrease GFR and renal perfusion, thereby reducing lithium excretion and requiring lower doses.[17]

Therapeutic Drug Monitoring (TDM)

The narrow gap between therapeutic and toxic concentrations makes TDM an absolute requirement for safe lithium use.[24] The goal of TDM is to maintain the serum lithium concentration within a target range that maximizes efficacy while minimizing the risk of toxicity.

• Therapeutic Ranges: While the general therapeutic range is often cited as 0.6 to 1.5 mEq/L, clinical practice involves tailoring the target to the specific indication and patient.[23]
• Acute Mania: A higher target range of 0.8 to 1.2 mEq/L is typically required for optimal effect.[18]
• Maintenance Therapy: A lower range of 0.6 to 1.0 mEq/L is usually sufficient for prophylaxis and is associated with better long-term tolerability.[18]
• Sample Timing: To ensure consistency and accurate interpretation, blood samples for lithium levels must be drawn as a 12-hour post-dose trough concentration (± 0.5 hours).[23] This standardized timing accounts for the drug's distribution phase and allows for meaningful comparison to established therapeutic ranges.

The entire clinical risk profile of lithium can be seen as a direct and predictable consequence of its pharmacokinetics. The fact that it is not metabolized places the full burden of elimination on the kidneys. This makes its clearance exquisitely sensitive to any changes in renal function, whether due to age, disease, or interacting drugs. Furthermore, its competition with sodium for reabsorption in the proximal tubule creates a dangerous vulnerability to changes in the body's salt and water balance. This causal chain explains precisely why common clinical scenarios—such as a patient developing gastroenteritis (dehydration), starting an NSAID for arthritis (reduced renal blood flow), or being prescribed a thiazide diuretic for hypertension (increased sodium reabsorption)—can rapidly precipitate lithium toxicity. This understanding transforms the management of lithium from simply prescribing a dose to managing a dynamic physiological system, requiring constant vigilance over the patient's hydration, diet, and concurrent medications.

---

Table 2: Key Pharmacokinetic Parameters and Factors Influencing Lithium Disposition

Parameter	Value / Description	Clinical Significance
Absorption (Tmax​)	IR: 0.25–3 hours; SR: 2–6 hours	Rapid absorption requires multiple daily doses for IR forms to maintain stable levels. SR forms allow for less frequent dosing.
Distribution (Vd​)	0.7–1.0 L/kg (approximates total body water)	Distributes widely. Dosing should be based on ideal body weight, especially for starting doses.
Metabolism	None; not metabolized by CYP450 enzymes	Avoids a major pathway for drug-drug interactions common with other psychotropics.
Excretion Route	>95% renal (unchanged in urine)	Elimination is almost entirely dependent on kidney function.
Elimination Half-life (t1/2​)	~24 hours (in adults with normal renal function)	Reaches steady state in ~5 days. Allows for once or twice daily maintenance dosing.
Protein Binding	Negligible / None	The entire plasma concentration is pharmacologically active.
Factors Affecting Levels	Effect on Lithium Level	Clinical Implication
Renal Impairment	Increases	Dose reduction is mandatory. Contraindicated in severe impairment.
Sodium Depletion / Dehydration	Increases	High risk of toxicity. Patient education on maintaining fluid/salt intake is critical.
Advanced Age	Increases	Requires lower doses and more cautious titration due to reduced renal function.
NSAIDs, ACE-I/ARBs	Increase	These common drug classes can precipitate toxicity and require close monitoring or avoidance.
Caffeine, Theophylline	Decrease	Can lead to sub-therapeutic levels. Patients should maintain consistent caffeine intake.

---

IV. Clinical Efficacy and Therapeutic Applications

Primary Indication: Bipolar I Disorder

Lithium carbonate is unequivocally established as a first-line agent for the management of Bipolar I Disorder, with FDA approval for both acute treatment and long-term maintenance.[22]

Acute Manic Episodes

Lithium is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder.[22] When administered to a patient experiencing mania, it typically produces a normalization of symptomatology—including pressured speech, motor hyperactivity, grandiosity, and poor judgment—within one to three weeks.[22] Its efficacy in this setting has been the cornerstone of its clinical use since its initial approval.

Maintenance Treatment

Perhaps even more important than its antimanic effect is its role as a maintenance therapy. Lithium is indicated to prevent or diminish the intensity of subsequent manic episodes in patients with a diagnosis of Bipolar I Disorder.[22] Its prophylactic efficacy is supported by robust evidence. A landmark meta-analysis published in 2004, which synthesized data from five randomized controlled trials involving 770 participants, provided definitive evidence of its superiority over placebo. The analysis found that lithium treatment significantly reduced the risk of any mood relapse (relative risk = 0.65) and was particularly effective in preventing manic relapses (RR = 0.62).[40] While a protective effect against depressive relapses was also observed, the effect size was smaller and did not achieve the same level of statistical robustness (RR = 0.72, 95% CI = 0.49 to 1.07).[32] This specific efficacy against mania is a defining feature of lithium's therapeutic profile.

Investigational and Off-Label Uses

Beyond its primary indication, lithium's unique properties have led to its investigation and off-label use in a variety of other psychiatric and medical conditions.

Major Depressive Disorder (MDD)

Although lithium is not considered effective as a monotherapy for unipolar major depression, it has a long history of off-label use as an augmentation strategy for patients with treatment-resistant depression (TRD).[8] Since the 1980s, it has been added to ongoing antidepressant therapy (e.g., with SSRIs) in patients who have not responded adequately to the antidepressant alone.[8] This remains one of its most common off-label applications.

Schizophrenia and Schizoaffective Disorder

The use of lithium in psychotic disorders is more complex. Clinical trials have explored its role, including at least one completed Phase 3 trial for schizophrenia where it was studied in combination with other agents.[43] However, evidence suggests its efficacy as a monotherapy is limited. It is generally considered only as an adjunctive therapy to antipsychotic medications in patients who have not responded adequately to antipsychotics alone.[18]

Other Investigational Uses

The clinical trial landscape reveals a broad range of ongoing and completed investigations into lithium's potential benefits in other disorders:

• Persistent Depressive Disorder (Dysthymia): A completed Phase 2 trial investigated the combination of lithium carbonate and citalopram for depressive mood disorder symptoms.[21]
• Alcohol Dependency: A completed Phase 3 trial examined the efficacy of lithium, quetiapine, and valproic acid in treating alcohol dependency in patients with comorbid bipolar disorder.[44]
• Acute Bipolar Depression: A completed Phase 3 trial compared the efficacy of quetiapine monotherapy to a combination of quetiapine plus lithium in treating acute bipolar depression.[45]
• Emerging Applications: The European clinical trials registry lists studies exploring lithium for a diverse set of conditions, including its use as a chemopreventive agent in Familial Adenomatous Polyposis, for treating lithium-induced nephrogenic diabetes insipidus, and in neurodevelopmental disorders like Phelan-McDermid Syndrome (a form of Autism Spectrum Disorder) and neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS).[46]

---

Table 3: Summary of Selected Clinical Trials for Key Indications

Indication	ClinicalTrials.gov ID	Phase	Status	Drugs Studied	Purpose / Title
Bipolar I Disorder (Maintenance)	NCT00667745 (LiTMUS)	4	Completed	Lithium Carbonate, Optimized Standard Medications	Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder 47
Acute Bipolar Depression	NCT00883493	3	Completed	Lithium Carbonate, Quetiapine	Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression 45
Schizophrenia (Mania Symptoms)	NCT00183443	3	Completed	Lithium Carbonate, Quetiapine, Valproic Acid	Treatment of Mania Symptoms With Drug Therapy 43
Alcohol Dependency & Bipolar I	NCT00114686	3	Completed	Lithium Carbonate, Quetiapine, Valproic Acid	Efficacy and Safety of Quetiapine in Alcohol Dependency with Bipolar Disorder 44
Persistent Depressive Disorder	NCT01189812	2	Completed	Lithium Carbonate, Citalopram	Safety and Efficacy Study of Citalopram and Lithium for Depressive Mood Disorder 21

---

A significant disconnect exists between lithium's established status as a highly effective, "gold standard" treatment and its observable decline in clinical use, particularly in North America.[5] This trend suggests that factors beyond pure efficacy—such as the burden of monitoring, tolerability concerns, and the heavy marketing of newer, patent-protected mood stabilizers—are powerfully influencing prescribing habits. The LiTMUS trial (NCT00667745) was a large, pragmatic study designed to address this issue in a real-world setting.[47] It sought to determine if adding a moderate, well-tolerated dose of lithium to an already optimized, personalized treatment regimen provided additional benefit compared to the optimized regimen alone. The results were nuanced and revealing: adding lithium did not confer a statistically significant symptomatic advantage over an already robust treatment plan. However, patients in the lithium group received second-generation antipsychotics significantly less often than those in the control group.[48] This finding reframes the clinical utility of lithium in the modern era of polypharmacy. It suggests that while it may not always be necessary to achieve symptom control, its inclusion can have a valuable "sparing" effect, potentially reducing a patient's exposure to other medications, like antipsychotics, which carry their own significant metabolic and long-term risks. This positions lithium not merely as a first-line agent but as a strategic component in a complex, personalized treatment algorithm, where its benefits must be weighed against its unique management requirements.

V. Clinical Administration and Management Protocols

Dosage Forms and Strengths

Lithium is available in a variety of oral formulations to allow for flexible and individualized dosing. These include immediate-release (IR) capsules in strengths of 150 mg, 300 mg, and 600 mg; IR tablets of 300 mg; extended-release (ER) tablets of 300 mg and 450 mg; and an oral solution containing 8 mEq of lithium ion per 5 mL.[18] The oral solution provides a useful alternative for patients who have difficulty swallowing tablets or capsules, with 8 mEq being bioequivalent to a 300 mg dose of lithium carbonate.[18]

Dosing and Titration

The administration of lithium is a highly individualized process, guided not by a fixed dose but by the achievement of a target serum concentration in conjunction with clinical response and patient tolerability.[37]

• Adults and Pediatrics over 30 kg: For acute mania, a typical starting dose is 300 mg three times daily for IR formulations or 900 mg twice daily for ER formulations.[18] The dose is then titrated upwards every few days as needed to achieve a target serum level of 0.8 to 1.2 mEq/L. The usual total daily dose for acute control is around 1800 mg.[37] For maintenance, the target serum level is lower, typically 0.8 to 1.0 mEq/L, with usual total daily doses ranging from 900 to 1200 mg.[18]
• Pediatrics (7+ years, 20 to 30 kg): Dosing is initiated at 300 mg twice daily. Titration is more gradual, typically increasing by 300 mg on a weekly basis, to achieve the same target serum concentrations as adults.[18]
• Geriatric Population: Dosing in the elderly must be approached with significant caution. Due to age-related decreases in renal function, lower starting doses and a slower titration schedule are required. Elderly patients often achieve therapeutic response at lower serum concentrations and are more susceptible to toxicity, even within the standard therapeutic range.[19]

---

Table 4: Recommended Dosing and Titration Schedules for Lithium Carbonate

Patient Population	Indication	Formulation	Starting Dose	Titration Schedule	Target Serum Concentration (mEq/L)
Adults & Peds >30 kg	Acute Mania	IR Capsules/Tablets	300 mg TID	300 mg every 3 days	0.8 to 1.2
		Oral Solution	8 mEq (5 mL) TID	8 mEq every 3 days	0.8 to 1.2
	Maintenance	IR Capsules/Tablets	300 mg TID	300 mg every 3 days	0.8 to 1.0
		Oral Solution	8 mEq (5 mL) TID	8 mEq every 3 days	0.8 to 1.0
Peds 20–30 kg	Acute Mania	IR Capsules/Tablets	300 mg BID	300 mg weekly	0.8 to 1.2
		Oral Solution	8 mEq (5 mL) BID	8 mEq weekly	0.8 to 1.2
	Maintenance	IR Capsules/Tablets	300 mg BID	300 mg weekly	0.8 to 1.0
		Oral Solution	8 mEq (5 mL) BID	8 mEq weekly	0.8 to 1.0
Source: Data compiled from.18 Dosing must be individualized based on clinical response and serum levels.

---

Pre-treatment Screening and Ongoing Monitoring

The safe use of lithium is predicated on a rigorous protocol of baseline screening and continuous long-term monitoring.

• Baseline Evaluation: Before initiating therapy, a comprehensive medical workup is mandatory. This includes an assessment of renal function (serum creatinine, BUN, urinalysis), thyroid function (TSH, T4), and serum electrolytes.[24] Vital signs should be recorded, and a baseline electrocardiogram (ECG) is recommended, particularly for patients over 40 or those with pre-existing cardiovascular risk factors.[36] For women of childbearing potential, pregnancy status must be evaluated.[34]
• Serum Lithium Monitoring: This is the cornerstone of lithium management. After initiation or any dose change, serum levels should be checked after 3-5 days to assess the approach to steady state. During the initial stabilization phase, levels should be monitored frequently, up to twice weekly.[19] Once the patient is stable on a maintenance dose, monitoring can be extended to every 2-3 months.[19] All blood samples must be drawn as a 12-hour post-dose trough level to ensure accurate and interpretable results.[23]
• Ongoing Systemic Monitoring: Long-term safety requires periodic re-evaluation of organ function. Renal function (creatinine) and thyroid function (TSH) should be checked at least every 6 to 12 months for the duration of treatment.[24] Serum calcium levels should also be monitored periodically due to the risk of lithium-induced hyperparathyroidism.[34]

The intensive and multi-faceted monitoring required for lithium therapy creates substantial practical hurdles. This regimen demands significant engagement and adherence from the patient, considerable time and diligence from the clinician, and resources from the healthcare system. Compared to many newer psychotropic agents that do not require therapeutic blood monitoring, the logistical complexity of lithium can be a powerful deterrent. This practical burden, a direct consequence of the drug's narrow therapeutic index and renal excretion, is a key driver of prescribing trends. It can lead clinicians and patients to opt for alternatives that may be less effective but are perceived as "easier" or safer to manage, highlighting a persistent tension between evidence-based efficacy and the pragmatic challenges of real-world clinical implementation.

VI. Comprehensive Safety Profile and Risk Mitigation

Overview of Adverse Reactions

Lithium is associated with a wide spectrum of adverse effects, ranging from common, benign symptoms that occur early in treatment to rare, but potentially life-threatening, toxicities. Many of the initial side effects, such as fine hand tremor, mild thirst, and nausea, may appear during the first few days of administration and often subside with continued treatment, temporary dose reduction, or administration with food.[34] However, the persistence or worsening of any side effect warrants clinical re-evaluation.

Common and Less Common Adverse Effects

Adverse reactions to lithium are numerous and affect multiple organ systems.

• Neurological: A fine hand tremor is one of the most common side effects, occurring particularly during initial therapy but potentially persisting.[51] Other common CNS effects include fatigue, drowsiness, muscle weakness, and cognitive side effects such as slowed thinking or a feeling of being "numb".[39]
• Renal: Polyuria (increased urine output) and polydipsia (excessive thirst) are extremely common, reported in up to 70% of patients on long-term therapy.[34] These symptoms result from lithium's interference with the action of antidiuretic hormone (ADH) on the renal collecting ducts, which can lead to nephrogenic diabetes insipidus (NDI). While NDI is usually reversible upon discontinuation of lithium, it requires careful management to prevent dehydration and subsequent lithium toxicity.[22] Of greater concern is the risk of long-term structural kidney damage. Chronic lithium therapy can be associated with chronic tubulointerstitial nephropathy, characterized by glomerular and interstitial fibrosis and nephron atrophy, which can lead to irreversible chronic kidney disease (CKD).[22]
• Gastrointestinal: Nausea, vomiting, diarrhea, and general abdominal discomfort are common, particularly at the beginning of treatment.[34] These symptoms can often be mitigated by taking lithium with food or using an extended-release formulation.[37]
• Endocrine: Thyroid dysfunction is a significant long-term risk. Lithium interferes with thyroid hormone synthesis and release, leading to hypothyroidism, often accompanied by a goiter (enlarged thyroid gland), in a substantial portion of patients.[34] Hyperthyroidism can also occur but is less common.[34] Another important endocrine effect is hyperparathyroidism, with associated hypercalcemia, which can develop with chronic use and requires monitoring of serum calcium levels.[34]
• Dermatologic: Lithium can induce or exacerbate acne and psoriasis. Hair loss or thinning is also a reported side effect.[39]
• Metabolic: Weight gain is a common and often distressing long-term side effect for many patients.[39]
• Cardiovascular: Benign and reversible T-wave flattening or inversion on the ECG is a common finding. More serious cardiovascular effects are rare but include sinus node dysfunction (bradycardia, sinus arrest) and, critically, the potential to unmask Brugada Syndrome, a latent genetic disorder that can cause life-threatening ventricular arrhythmias and sudden cardiac death.[22]

---

Table 5: Adverse Reactions to Lithium Therapy by Frequency and System Organ Class

System Organ Class	Very Common (>10%)	Common (1-10%)	Rare / Incidence Not Known (<1%)
Neurological	Fine hand tremor, Polyuria, Polydipsia, Headache, Drowsiness, Fatigue	Ataxia/gait disturbance, Muscle weakness, Slurred speech, Memory impairment, Confusion	Seizures, Blackouts, Pseudotumor cerebri (benign intracranial hypertension), Encephalopathic syndrome, Nystagmus, Choreoathetotic movements, Peripheral neuropathy
Renal	Polyuria (frequent urination), Polydipsia (increased thirst)	Nephrogenic diabetes insipidus	Chronic kidney disease, Interstitial nephritis, Renal failure, Nephrotic syndrome
Gastrointestinal	Nausea, Diarrhea, Abdominal discomfort	Vomiting, Dry mouth, Metallic taste, Dysgeusia	Swollen salivary glands, Gastritis
Endocrine	Increased TSH	Hypothyroidism (with or without goiter), Weight gain	Hyperthyroidism, Hyperparathyroidism, Hypercalcemia
Cardiovascular	Benign ECG changes (T-wave flattening/inversion)	Bradycardia, Arrhythmias	Unmasking of Brugada Syndrome, Sick sinus syndrome, Hypotension, Myocarditis
Dermatologic	Acne, Psoriasis (exacerbation)	Rash, Hair loss/thinning	Alopecia, Folliculitis
Hematologic	Leukocytosis (benign)		Aplastic anemia, Agranulocytosis
Metabolic		Weight gain	Hyperglycemia, Hyponatremia
Source: Data compiled from.34

---

Lithium Toxicity (Overdose)

Lithium toxicity is a medical emergency that can result in permanent neurological injury or death. It occurs when serum lithium concentrations rise to excessive levels, either from an intentional or accidental acute overdose, or more commonly, from a gradual accumulation due to factors that impair its excretion.[35]

Clinical Presentation

The symptoms of toxicity are often an intensification of the drug's common side effects, progressing along a continuum of severity that correlates with the serum level.

• Mild Toxicity (serum level ~1.5–2.0 mEq/L): Patients may experience worsening of nausea, vomiting, and diarrhea, along with increasing lethargy, drowsiness, coarse hand tremor, muscle weakness, and ataxia (unsteady gait).[22]
• Moderate Toxicity (serum level ~2.0–2.5 mEq/L): Symptoms progress to include significant confusion, blurred vision, marked ataxia, stupor, rigidity, hyperreflexia, and myoclonic jerks.[24]
• Severe Toxicity (serum level >2.5 mEq/L): This is a life-threatening state characterized by coma, generalized convulsions, cardiovascular collapse, and acute renal failure.[24]

A particularly feared complication is the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT), a condition where severe, persistent neurological deficits (especially cerebellar signs like ataxia and dysarthria) remain even after lithium has been completely cleared from the body.58

Management of Toxicity

Any suspicion of lithium toxicity requires immediate medical intervention.

1. Discontinuation: The first step is to stop lithium administration immediately.[35]
2. Supportive Care: Management focuses on supportive measures, including aggressive intravenous hydration with normal saline to restore fluid and electrolyte balance and promote renal excretion of lithium.[35]
3. Extracorporeal Treatment (Hemodialysis): For moderate to severe toxicity, supportive care alone is insufficient. Lithium is highly dialyzable, and intermittent hemodialysis is the definitive and most effective treatment for rapidly removing lithium from the body.[58] The clearance of lithium by hemodialysis (mean 106.9 mL/min) is approximately tenfold greater than endogenous renal clearance (mean 10.6 mL/min).[58] Strong recommendations exist for initiating hemodialysis in patients with severe neurological symptoms (e.g., seizures, coma), those with acute or chronic renal failure, or when serum levels are very high (generally >4.0 mEq/L, or >5.0 mEq/L in some guidelines), irrespective of symptoms.[58] Dialysis should be continued until the serum level is well within the therapeutic range (e.g., <1.0 mEq/L) and clinical symptoms have improved.[58]

The clinical presentation of lithium toxicity represents a dangerous continuum, where the early warning signs are simply a worsening of the drug's common therapeutic side effects. A fine hand tremor becomes a coarse, debilitating tremor; mild nausea progresses to persistent vomiting; and drowsiness deepens into stupor and coma. This lack of a distinct, novel "alarm" symptom for early toxicity creates a significant risk, as patients or even clinicians might dismiss worsening side effects as a tolerable nuisance, allowing toxicity to progress to a severe and potentially irreversible state. This underscores the absolute necessity of comprehensive patient education. Patients and their families must be explicitly instructed that any sudden worsening of side effects, especially when accompanied by new neurological signs like unsteadiness, slurred speech, or confusion, is a potential medical emergency that requires them to stop the medication and seek immediate medical attention.[22]

VII. Clinically Significant Drug and Disease Interactions

Overview

The safe use of lithium is critically dependent on an awareness of its numerous and clinically significant interactions. With over 700 known drug interactions, of which nearly 200 are classified as major, careful medication reconciliation is essential.[59] These interactions can be broadly categorized into those that alter lithium's pharmacokinetics, thereby changing its serum level, and those that alter its pharmacodynamics, potentiating its adverse effects.

Pharmacokinetic Interactions (Altering Lithium Levels)

These interactions are the most common and dangerous, as they can unpredictably shift a patient from a therapeutic to a toxic or sub-therapeutic state. The majority occur via effects on renal function.[61]

Drugs that INCREASE Lithium Levels (Increased Risk of Toxicity)

• Diuretics: These are among the most well-known and dangerous interactants. Thiazide diuretics (e.g., hydrochlorothiazide) are particularly problematic as they significantly reduce renal lithium clearance. Loop diuretics (e.g., furosemide) and potassium-sparing diuretics (e.g., spironolactone) also increase lithium retention and require close monitoring or avoidance.[61]
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Commonly used over-the-counter and prescription pain relievers such as ibuprofen, naproxen, diclofenac, and celecoxib can decrease renal blood flow and GFR by inhibiting prostaglandin synthesis. This impairs lithium excretion and can lead to a significant rise in serum levels.[39]
• Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin-II Receptor Blockers (ARBs): This class of antihypertensives (e.g., lisinopril, ramipril, losartan, valsartan) alters renal hemodynamics and promotes sodium excretion, which leads to compensatory lithium retention. Co-administration requires frequent monitoring and often a reduction in lithium dosage.[24]
• Antibiotics: Certain antibiotics, notably metronidazole and tetracyclines, have been reported to decrease lithium clearance and increase the risk of toxicity.[61]

Drugs that DECREASE Lithium Levels (Increased Risk of Inefficacy)

• Xanthine Derivatives: Agents like theophylline (used for asthma) and caffeine significantly increase the renal clearance of lithium, which can lower serum concentrations below the therapeutic threshold, leading to loss of efficacy and potential mood episode relapse.[24] Patients should be advised to maintain a consistent daily intake of caffeine.
• Alkalinizing Agents: Substances that increase urinary pH, such as sodium bicarbonate or potassium citrate, can enhance lithium excretion and lower its levels.[61]

Pharmacodynamic Interactions (Potentiating Adverse Effects)

These interactions occur when another drug adds to or synergizes with lithium's effects on the body, particularly the central nervous system.

• Serotonin Syndrome: Combining lithium with other serotonergic agents creates a risk of this potentially fatal syndrome, characterized by mental status changes, autonomic hyperactivity, and neuromuscular abnormalities. High-risk combinations include SSRIs (e.g., fluoxetine, sertraline), SNRIs, triptans, tramadol, and St. John's Wort.[19]
• Neurotoxicity: The risk of CNS toxicity, including confusion, tremor, extrapyramidal symptoms, and a severe encephalopathic syndrome resembling Neuroleptic Malignant Syndrome (NMS), is increased when lithium is co-administered with other neuroactive drugs. This is a particular concern with antipsychotics (especially first-generation agents like haloperidol, but also newer agents), as well as carbamazepine and calcium channel blockers.[29]
• QTc Interval Prolongation: Lithium itself can affect cardiac conduction. Its risk of causing arrhythmias is heightened when used with other drugs known to prolong the QTc interval, such as the antipsychotics thioridazine and pimozide, certain antiarrhythmics, and some antibiotics.[19]

---

Table 6: A Guide to Clinically Significant Drug-Drug Interactions with Lithium

Interacting Drug / Class	Effect on Lithium	Mechanism	Clinical Management Recommendation	Severity
Thiazide Diuretics (e.g., HCTZ)	↑ Level	Decreased renal clearance	Avoid combination if possible. If necessary, reduce lithium dose and monitor levels very frequently.	Major
NSAIDs (e.g., Ibuprofen, Naproxen)	↑ Level	Decreased renal clearance	Avoid routine use. For occasional use, monitor lithium levels closely. Acetaminophen is a safer alternative for analgesia.	Major
ACE Inhibitors / ARBs (e.g., Lisinopril)	↑ Level	Decreased renal clearance	Frequent monitoring of lithium levels and renal function is required. Lithium dose reduction is often necessary.	Major
Metronidazole	↑ Level	Decreased renal clearance	Monitor for signs of toxicity.	Moderate
Caffeine / Theophylline	↓ Level	Increased renal clearance	Advise patient to maintain consistent daily caffeine intake. Monitor for loss of efficacy if intake changes.	Moderate
Antipsychotics (esp. Haloperidol)	↑ Neurotoxicity	Pharmacodynamic synergism	Monitor closely for signs of neurotoxicity (confusion, tremor, rigidity). May require discontinuation of one or both agents.	Major
SSRIs / Serotonergic Agents	↑ Serotonin Syndrome	Pharmacodynamic synergism	Monitor closely for symptoms of serotonin syndrome (agitation, hyperthermia, myoclonus).	Moderate
Carbamazepine	↑ Neurotoxicity	Pharmacodynamic synergism	Monitor for signs of neurotoxicity (ataxia, dizziness, confusion).	Moderate
Source: Data compiled from.34 Severity classification is based on common clinical guidelines.

---

Interactions with Disease, Diet, and Supplements

• Disease States: The risk of lithium toxicity is profoundly increased in patients with underlying disease, particularly renal disease, cardiovascular disease, and any condition that predisposes to dehydration or electrolyte imbalance (e.g., severe diarrhea, fever).[17]
• Diet and Lifestyle: Patients must be counseled to maintain a stable and adequate intake of both salt and fluids. A sudden switch to a low-sodium diet can precipitate toxicity. Dehydration from excessive sweating during exercise or in hot weather is also a significant risk.[38]
• Herbal Supplements: The use of herbal supplements should be approached with extreme caution. St. John's Wort can contribute to serotonin syndrome.[38] Herbal products with diuretic properties (often found in weight-loss formulas) can cause dehydration and lead to dangerous increases in lithium levels.[62]

The vast list of over 700 potential drug interactions can seem daunting. However, a mechanistic understanding provides a more powerful framework for risk management than rote memorization. The overwhelming majority of clinically critical interactions are pharmacokinetic in nature and stem from a predictable effect on the kidney's handling of salt and water. Therefore, a clinician can adopt a simple but highly effective heuristic when considering any new medication for a patient on lithium: "Does this drug affect renal function, fluid balance, or sodium levels?" If the answer is yes—as it is for diuretics, NSAIDs, and ACE inhibitors—an interaction is highly probable and demands proactive management, such as more frequent blood level monitoring and potential dose adjustments. This approach shifts clinical practice from being reactive (looking up a specific drug after the fact) to being proactive (screening all new agents for a high-risk mechanism of action), thereby empowering clinicians to more effectively prevent lithium toxicity.

VIII. Use in Special and Vulnerable Populations

The administration of lithium in special populations requires heightened vigilance, individualized risk-benefit analysis, and a departure from standard protocols. In these groups, the therapeutic window can become narrower and less predictable, demanding expert clinical judgment supported by intensive monitoring.

Pregnancy and Lactation

Pregnancy

Lithium is classified by the FDA as Pregnancy Category D, indicating that there is positive evidence of human fetal risk based on human data, but the potential benefits from use in pregnant women may be acceptable despite the risk.[36] Lithium readily crosses the placental barrier. Exposure during the first trimester of pregnancy has been associated with an increased risk of congenital cardiac malformations, most notably

Ebstein's anomaly, a rare defect of the tricuspid valve.[22] While early data suggested a significant risk, more recent data indicate the absolute risk is low. The decision to use lithium during pregnancy involves a complex discussion, weighing this fetal risk against the substantial risk of maternal relapse and its associated morbidity if a highly effective mood stabilizer is discontinued. If lithium therapy is continued, close collaboration between the psychiatrist and obstetrician is essential. Serum lithium levels must be monitored frequently (e.g., monthly in early pregnancy, weekly near term) as GFR increases during pregnancy, often necessitating a dose increase to maintain therapeutic levels. To reduce the risk of neonatal toxicity, the dose is often reduced or discontinued 2-3 days before the expected delivery date and restarted postpartum.[18]

Lactation

Lithium is excreted into human breast milk, with infant serum concentrations reaching 30-50% of maternal levels. Because of the potential for toxicity in the infant (including lethargy, hypotonia, and cyanosis), breastfeeding is generally not recommended for mothers taking lithium. It should only be considered in rare and unusual circumstances where, in the physician's judgment, the potential benefits to the mother clearly outweigh the possible hazards to the child.[22]

Pediatric Population

Historically considered unsuitable for children, lithium is now FDA-approved for the treatment of Bipolar I Disorder in pediatric patients aged 7 years and older.[11] The safety and effectiveness in children under the age of 7 have not been established.[36] The pharmacokinetics of lithium differ in children, who tend to have a more rapid metabolism and greater renal clearance compared to adults. This may necessitate higher weight-based doses (mg/kg) to achieve therapeutic serum concentrations.[17] Dosing is typically initiated based on body weight, with children weighing 20-30 kg starting at 300 mg twice daily, while those over 30 kg can follow adult dosing guidelines.[18] The profile of adverse reactions is generally similar to that in adults, although studies suggest that nausea/vomiting, polyuria/polydipsia, and thyroid abnormalities may be more frequently reported in the pediatric population.[34]

Geriatric Population

Elderly patients represent a population of special concern and vulnerability when it comes to lithium therapy. Age-related physiological changes, including a natural decline in renal function and a decrease in total body water, lead to reduced lithium clearance and a smaller volume of distribution.[17] Consequently, elderly patients often require significantly lower doses to achieve therapeutic serum levels. Furthermore, they are more sensitive to lithium's adverse effects and may exhibit signs of neurotoxicity at serum concentrations that would be considered well within the therapeutic range for younger adults.[19] Dosing in this population should always follow the principle of "start low and go slow," with cautious titration and vigilant monitoring for both therapeutic and adverse effects.

Patients with Comorbidities

The presence of significant medical comorbidities dramatically increases the risk associated with lithium therapy.

• Renal Disease: This is the most critical comorbidity. Given that lithium is almost exclusively eliminated by the kidneys, any pre-existing renal impairment is a major concern. Lithium is contraindicated in patients with severe renal disease (CLcr < 30 mL/min).[29] In patients with mild to moderate renal impairment, lithium must be used with extreme caution, starting with very low doses and requiring more frequent monitoring of both serum lithium levels and renal function.[34]
• Cardiovascular Disease: Lithium should be used with great caution in patients with significant cardiovascular disease due to its potential to cause arrhythmias and sinus node dysfunction, and to unmask Brugada Syndrome.[22]
• Thyroid Disease: A pre-existing thyroid disorder is not an absolute contraindication to lithium use. However, because lithium can interfere with thyroid function, it requires very careful monitoring of thyroid parameters (TSH) to allow for correction of any changes that may occur during treatment.[36]

The use of lithium in these special populations highlights a crucial clinical principle: the standard therapeutic range is a guideline, not an absolute rule. It is a statistical construct derived from studies in general adult populations. In patients with altered physiology—whether due to pregnancy, age, or disease—this window becomes less reliable. The risk of fetal harm in pregnancy, the heightened sensitivity to toxicity in the elderly, and the unpredictable clearance in renal disease mean that the clinician cannot rely solely on the laboratory value. Instead, the serum level must be interpreted within the full clinical context of the individual patient. This makes the management of lithium in these groups a true exercise in the "art" of medicine, demanding a higher level of expertise, more nuanced clinical judgment, and a therapeutic plan that prioritizes individualized assessment over rigid protocols.

IX. Emerging Research and Future Directions

Despite being one of the oldest medications in modern psychopharmacology, lithium remains at the forefront of psychiatric and neuroscience research. Current investigations are proceeding along two complementary tracks: one exploring its potential in new therapeutic areas, particularly neurodegeneration, and the other using advanced tools to refine its clinical use and deepen our understanding of its fundamental mechanisms in mood disorders.

The Neuroprotective Frontier

A growing body of preclinical and clinical evidence has repositioned lithium from a simple mood stabilizer to a potential disease-modifying agent for a range of devastating neurodegenerative disorders.[2] This paradigm shift is grounded in its known molecular actions: the inhibition of GSK-3β, promotion of cellular waste-clearing processes like autophagy, reduction of oxidative stress and neuroinflammation, and the upregulation of critical neurotrophic factors like BDNF.[26]

Alzheimer's Disease (AD)

Alzheimer's disease is arguably the most exciting new frontier for lithium research. Preclinical models have consistently shown that lithium can reduce two of the core pathologies of AD: the formation of amyloid-β plaques and the hyper-phosphorylation of tau protein, which forms neurofibrillary tangles.[32]

A groundbreaking study from Harvard Medical School, published in Nature in 2025, proposed a revolutionary new hypothesis for both the pathogenesis of AD and the mechanism of lithium.[64] This research established for the first time that lithium is a naturally occurring and essential trace element in the human brain. The study found that a depletion of this endogenous brain lithium is one of the earliest detectable events in the development of AD. The researchers demonstrated that toxic amyloid-β plaques act as a "sink," sequestering lithium and preventing it from performing its normal neuroprotective functions.[64] This finding also provides a compelling explanation for the mixed results and toxicity seen in previous clinical trials of lithium carbonate for AD; at the high doses required, the standard lithium compounds were being trapped by the plaques before they could exert a therapeutic effect, while the unbound excess caused side effects.[64]

The same Harvard study identified a novel formulation, lithium orotate, which was able to evade capture by the amyloid plaques. In mouse models of AD, treatment with lithium orotate—at doses a thousand times lower than those used for bipolar disorder—reversed AD pathology, prevented cell death, and restored memory function without evidence of toxicity.[64] While these findings require confirmation in human clinical trials, they point toward a future where measuring brain lithium levels could be a screening tool for AD and where low-dose, amyloid-evading lithium compounds could be used for prevention or treatment.

Other Neurodegenerative Diseases

Lithium's neuroprotective potential has also been investigated in other conditions. Preclinical data for Parkinson's Disease and Huntington's Disease are promising.[32] However, translation to clinical success has been challenging. Multiple clinical trials of lithium for Amyotrophic Lateral Sclerosis (ALS), for instance, have yielded inconsistent or negative results, failing to confirm the benefits seen in animal models.[32]

Landmark Clinical Trials: Deeper Insights into Clinical Use

Parallel to the research into new applications, major clinical trials are helping to refine our understanding of how to best use lithium for its primary indication, bipolar disorder.

The LiTMUS Study (NCT00667745)

The Lithium Treatment-Moderate Dose Use Study (LiTMUS) was a large-scale, pragmatic, randomized trial designed to answer a critical real-world question about lithium's place in modern, combination-therapy-focused practice.[47] The study enrolled 283 outpatients with bipolar disorder and randomized them to receive either optimized personalized treatment (OPT)

plus a moderate, well-tolerated dose of lithium, or OPT alone for six months.[48] The primary outcomes were overall illness severity and the number of medication adjustments needed.[48]

The results were highly informative. The study found no significant symptomatic advantage for adding lithium to an already optimized treatment regimen.[48] However, it revealed a crucial difference in treatment patterns: the group receiving lithium had

significantly less exposure to second-generation antipsychotics (48.3% vs. 62.5% in the OPT-alone group).[48] A sobering finding from the trial was that only about a quarter of patients in either highly managed group achieved sustained remission, underscoring the profound and persistent nature of bipolar disorder.[48] The LiTMUS trial provides a vital, real-world perspective, suggesting that lithium's role may be not only to improve symptoms but also to act as a "cornerstone" agent that alters the overall composition of a patient's regimen, potentially sparing them from the metabolic and other risks of long-term antipsychotic use.

The Brain Connectome Study (NCT03336918)

This ongoing observational study represents the "micro" level of lithium research, using cutting-edge neuroimaging to understand how lithium works in the brain.[67] The study is enrolling patients with Bipolar II depression and using high-powered 7-Tesla functional MRI (fMRI) and diffusion tensor imaging (DTI) to map the brain's functional and structural connectivity before and during 26 weeks of lithium monotherapy.[69] The primary goal is to identify changes in brain network properties and correlate them with clinical improvements in mood and with changes in peripheral gene expression.[67]

While results from this specific study are still pending, related research has already shown that lithium appears to have a "normalizing" effect on brain connectivity in bipolar disorder. It helps to correct abnormal activity in key brain circuits involved in emotion regulation, such as prefrontal-striatal and cortico-limbic pathways.[31] Some studies suggest lithium may normalize this connectivity more rapidly than other mood stabilizers like quetiapine.[70] This line of research holds the promise of moving beyond subjective clinical observation to identify objective, biological markers of lithium's effects. Such biomarkers could one day be used to predict which patients will respond, monitor treatment efficacy in real time, and guide the development of new drugs that mimic lithium's specific effects on brain networks.

The future of lithium research is thus proceeding along two vital and complementary paths. "Macro" level pragmatic trials like LiTMUS are defining its optimal role within the complex, real-world practice of psychiatric polypharmacy. Simultaneously, "micro" level neurobiological investigations like the Connectome study and the Alzheimer's research are seeking to unravel its fundamental mechanisms of action. This dual-track approach ensures that this very old drug remains a subject of intense scientific interest and at the forefront of psychiatric innovation, being both optimized for today's clinic and re-examined for its potential to unlock the treatments of tomorrow.

X. Synthesis and Expert Recommendations

Integrated Summary

Lithium carbonate stands as an undisputed cornerstone of modern psychopharmacology. Its journey from an ancient folk remedy to the gold standard for bipolar disorder is a testament to its profound and specific therapeutic power. Decades of clinical use and research have solidified its reputation for unparalleled efficacy in preventing manic relapse, and a growing body of evidence is now revealing its exciting potential as a neuroprotective and even disease-modifying agent for neurodegenerative disorders.

This efficacy, however, is inextricably linked to a challenging clinical profile. Lithium is defined by the precarious balance between benefit and risk. Its narrow therapeutic index, which leaves little room for error between an effective dose and a toxic one, mandates a level of clinical vigilance unmatched by most other psychotropics. The demanding schedule of blood level monitoring, the extensive list of potential adverse effects affecting nearly every organ system, and the multitude of clinically significant drug and disease interactions all contribute to a significant management burden. The safe and effective use of lithium, therefore, is not merely a matter of prescribing; it is a hallmark of expert clinical practice, requiring a deep understanding of its pharmacology, a commitment to proactive monitoring, and a strong therapeutic alliance with the patient.

Actionable Recommendations for Clinicians

Based on the comprehensive evidence reviewed, the following recommendations are provided to guide the clinical use of lithium carbonate:

1. Prioritize Patient Selection: The greatest benefit from lithium is likely to be seen in patients with classic, episodic Bipolar I Disorder, particularly those with a history of euphoric mania and a clear pattern of wellness between episodes. Exercise extreme caution and consider alternative agents in patients with significant pre-existing renal disease (contraindicated if CLcr < 30 mL/min), unstable cardiovascular disease, or in those who require concurrent treatment with strongly interacting medications like thiazide diuretics or NSAIDs.
2. Embrace Individualized Treatment: Reject a "one-size-fits-all" approach to dosing. The goal is not simply to achieve a number within the standard therapeutic range, but to find the lowest effective serum concentration for each individual patient that provides mood stability while minimizing adverse effects. Titrate the dose meticulously, guided by both serum levels and clinical response, and be prepared to use lower target levels (e.g., 0.6–0.8 mEq/L) for long-term maintenance to improve tolerability.
3. Make Education a Core Component of Therapy: Patient and family education is not an adjunct to treatment; it is critical to safety. Clinicians must ensure that patients can recognize the early signs of toxicity (e.g., worsening tremor, diarrhea, vomiting, ataxia, confusion) and understand that these constitute a medical emergency. Emphasize the absolute importance of maintaining consistent fluid and salt intake, avoiding dehydration, and immediately reporting any new illnesses (especially those causing fever or GI distress) or the initiation of any new medications, including over-the-counter products.
4. Adhere to Rigorous Monitoring Protocols: The safety of long-term lithium therapy depends on unwavering adherence to monitoring guidelines. This includes frequent serum level checks during stabilization and regular (e.g., every 6-12 months) assessment of renal (serum creatinine) and thyroid (TSH) function for the entire duration of treatment. Periodic monitoring of serum calcium is also warranted.
5. Utilize Lithium Strategically in Polypharmacy: In the context of modern treatment, where combination therapy is common, consider the findings of the LiTMUS trial. While adding lithium may not always provide additional symptomatic benefit to an already optimized regimen, its use may allow for a reduction in the dose or need for other medications, particularly second-generation antipsychotics, thereby sparing the patient from a different set of long-term risks.

Imperatives for Future Research

To continue to build on lithium's legacy and unlock its full potential, the following research imperatives should be prioritized:

1. Confirm the Neuroprotective Role: The promising preclinical and early clinical findings for lithium's role in neurodegeneration, particularly Alzheimer's disease, must be tested in large-scale, long-term, randomized controlled trials in humans. These studies are urgently needed to determine if lithium can truly prevent or modify the course of these devastating illnesses.
2. Develop Safer Formulations and Analogs: Research into novel lithium compounds, such as lithium orotate, or new delivery systems that could potentially offer an improved therapeutic index (i.e., a wider gap between effective and toxic doses) should be a high priority. The goal is to harness lithium's therapeutic mechanisms while mitigating its systemic toxicities.
3. Identify and Validate Biomarkers: Continued investment in research using advanced neuroimaging, genomic, and molecular techniques is essential to identify reliable biomarkers that can predict treatment response and monitor therapeutic effects. The ability to objectively determine which patients are most likely to benefit from lithium and to track its neurobiological impact would represent a monumental step toward personalized medicine in psychiatry, finally allowing clinicians to fully and safely leverage the power of this remarkable and enduring therapeutic agent.

Works cited

1. A Brief History of Lithium Treatment in Psychiatry - Psychiatrist.com, accessed August 12, 2025, https://www.psychiatrist.com/pcc/history-of-lithium-treatment-in-psychiatry/
2. An Overview of the Effects of Lithium on Alzheimer's Disease: A Historical Perspective, accessed August 12, 2025, https://www.mdpi.com/1424-8247/18/4/532
3. Lithium Carbonate: The Penicillin of Psychiatry | Psychology Today Canada, accessed August 12, 2025, https://www.psychologytoday.com/ca/blog/freud-fluoxetine/201908/lithium-carbonate-the-penicillin-psychiatry
4. Lithium: Past, Present, and Future - Psychiatric Times, accessed August 12, 2025, https://www.psychiatrictimes.com/view/lithium-past-present-and-future
5. The history of lithium therapy - PMC, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3712976/
6. The Effect and Mechanism of Lithium Carbonate on Bipolar Disorder and its Immunological Contributions - Athenaeum Scientific Publishers, accessed August 12, 2025, https://athenaeumpub.com/the-effect-and-mechanism-of-lithium-carbonate-on-bipolar-disorder-and-its-immunological-contributions/
7. Full article: Why lithium should be used in patients with bipolar disorder? A scoping review and an expert opinion paper, accessed August 12, 2025, https://www.tandfonline.com/doi/full/10.1080/14737175.2022.2161895
8. Lithium (medication) - Wikipedia, accessed August 12, 2025, https://en.wikipedia.org/wiki/Lithium_(medication)
9. Current Drug Information: Lithium Carbonate: Annals of Internal ..., accessed August 12, 2025, https://www.acpjournals.org/doi/10.7326/0003-4819-73-2-291
10. The History of Lithium - Psych Education, accessed August 12, 2025, https://psycheducation.org/the-history-of-lithium/
11. Lithium Pediatric Postmarketing Safety Review - FDA, accessed August 12, 2025, https://www.fda.gov/media/181811/download
12. Lithium carbonate | CAS 554-13-2 | SCBT, accessed August 12, 2025, https://www.scbt.com/p/lithium-carbonate-554-13-2
13. Lithium carbonate | Dilithium carbonate | Li2CO3 - Ereztech, accessed August 12, 2025, https://ereztech.com/product/lithium-carbonate-554-13-2/
14. www.tcichemicals.com, accessed August 12, 2025, https://www.tcichemicals.com/OP/en/p/L0224
15. Lithium Carbonate | Li2CO3 | CID 11125 - PubChem, accessed August 12, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lithium-Carbonate
16. Lithium carbonate - Wikipedia, accessed August 12, 2025, https://en.wikipedia.org/wiki/Lithium_carbonate
17. The Pharmacokinetics of Lithium - Neupsy Key, accessed August 12, 2025, https://neupsykey.com/the-pharmacokinetics-of-lithium/
18. Lithium Carbonate: Package Insert / Prescribing Information, accessed August 12, 2025, https://www.drugs.com/pro/lithium-carbonate.html
19. Eskalith, Lithobid (lithium) dosing, indications, interactions, adverse effects, and more, accessed August 12, 2025, https://reference.medscape.com/drug/eskalith-lithobid-lithium-342934
20. File:Lithium-carbonate2DCSD.svg - Wikipedia, accessed August 12, 2025, https://en.m.wikipedia.org/wiki/File:Lithium-carbonate2DCSD.svg
21. Persistent Depressive Disorder (Dysthymia) Completed Phase 2 Trials for Lithium carbonate (DB14509) | DrugBank Online, accessed August 12, 2025, https://go.drugbank.com/indications/DBCOND0128618/clinical_trials/DB14509?phase=2&status=completed
22. LITHIUM CARBONATE Tablets USP, LITHIUM CARBONATE Capsules USP, LITHIUM Oral Solution USP - accessdata.fda.gov, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017812s028,018421s027lbl.pdf
23. Lithium | Applied Clinical Pharmacokinetics, 3e | AccessPharmacy | McGraw Hill Medical, accessed August 12, 2025, https://accesspharmacy.mhmedical.com/content.aspx?bookid=1374§ionid=74721492
24. Bipolar Disorders and Lithium: Pharmacokinetics, Pharmacodynamics, Therapeutic Effects and Indications of Lithium: Review of Articles - Austin Publishing Group, accessed August 12, 2025, https://austinpublishinggroup.com/psychiatry-behavioral-sciences/fulltext/ajpbs-v3-id1053.php
25. LITHIUM IN THE TREATMENT OF BIPOLAR DISORDER: PHARMACOLOGY AND PHARMACOGENETICS - PMC - PubMed Central, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5125816/
26. Neuroprotective Effects of Lithium: Implications for the Treatment of Alzheimer's Disease and Related Neurodegenerative Disorders - PubMed Central, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4063497/
27. A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts, accessed August 12, 2025, https://www.dovepress.com/a-new-look-at-an-old-drug-neuroprotective-effects-and-therapeutic-pote-peer-reviewed-fulltext-article-NDT
28. Antiviral, immunomodulatory, and neuroprotective effect of lithium - IMR Press, accessed August 12, 2025, https://www.imrpress.com/journal/JIN/21/2/10.31083/j.jin2102068/htm
29. Lithium - StatPearls - NCBI Bookshelf, accessed August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK519062/
30. Chapter 17. Lithium | Applied Clinical Pharmacokinetics, 2e | AccessPharmacy, accessed August 12, 2025, https://accesspharmacy.mhmedical.com/content.aspx?bookid=510§ionid=40843106
31. The Impact of Lithium on Brain Function in Bipolar Disorder: An ..., accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9537229/
32. Potential application of lithium in Parkinson's and other ... - Frontiers, accessed August 12, 2025, https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2015.00403/full
33. A Review for Lithium: Pharmacokinetics, Drug Design and Toxicity - ResearchGate, accessed August 12, 2025, https://www.researchgate.net/publication/337271726_A_Review_for_Lithium_Pharmacokinetics_Drug_Design_and_Toxicity
34. Lithium - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017812s033,018421s032,018558s027lbl.pdf
35. Lithium toxicity: Symptoms, causes, complications, and treatment - Medical News Today, accessed August 12, 2025, https://www.medicalnewstoday.com/articles/327145
36. What are the special population considerations for lithium (lithium carbonate) therapy?, accessed August 12, 2025, https://www.droracle.ai/articles/79138/what-is-special-population-consideration-for-lithium
37. Lithium Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 12, 2025, https://www.drugs.com/dosage/lithium.html
38. Lithium (Eskalith): Uses & Side Effects - Cleveland Clinic, accessed August 12, 2025, https://my.clevelandclinic.org/health/drugs/18665-lithium-capsules-or-tablets
39. Lithium: MedlinePlus Drug Information, accessed August 12, 2025, https://medlineplus.gov/druginfo/meds/a681039.html
40. Long-Term Lithium Therapy for Bipolar Disorder: Systematic Review and Meta-Analysis of Randomized Controlled Trials | American Journal of Psychiatry, accessed August 12, 2025, https://psychiatryonline.org/doi/full/10.1176/appi.ajp.161.2.217
41. en.wikipedia.org, accessed August 12, 2025, https://en.wikipedia.org/wiki/Lithium_(medication)#:~:text=It%20is%20sometimes%20used%20when,such%20use%20is%20off%2Dlabel.
42. Common questions about lithium - NHS, accessed August 12, 2025, https://www.nhs.uk/medicines/lithium/common-questions-about-lithium/
43. Schizophrenia Completed Phase 3 Trials for Lithium carbonate (DB14509) - DrugBank, accessed August 12, 2025, https://go.drugbank.com/indications/DBCOND0018504/clinical_trials/DB14509?phase=3&status=completed
44. Lithium carbonate Completed Phase 3 Trials for Alcohol Dependency / Bipolar 1 Disorder Treatment - DrugBank, accessed August 12, 2025, https://go.drugbank.com/drugs/DB14509/clinical_trials?conditions=DBCOND0071586%2CDBCOND0020745&phase=3&purpose=treatment&status=completed
45. Lithium carbonate Completed Phase 3 Trials for Acute Bipolar Depression Treatment, accessed August 12, 2025, https://go.drugbank.com/drugs/DB14509/clinical_trials?conditions=DBCOND0043509&phase=3&purpose=treatment&status=completed
46. Search for Lithium - Clinical Trials register, accessed August 12, 2025, https://www.clinicaltrialsregister.eu/ctr-search/search?query=Lithium
47. Study Details | Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder | ClinicalTrials.gov, accessed August 12, 2025, https://clinicaltrials.gov/study/NCT00667745
48. Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium - PubMed, accessed August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/23288387/
49. (PDF) Lithium Treatment Moderate-Dose Use Study (LiTMUS) for ..., accessed August 12, 2025, https://www.researchgate.net/publication/234047800_Lithium_Treatment_Moderate-Dose_Use_Study_LiTMUS_for_Bipolar_Disorder_A_Randomized_Comparative_Effectiveness_Trial_of_Optimized_Personalized_Treatment_With_and_Without_Lithium
50. Lithium Toxicity: What It Is, Causes, Symptoms & Treatment - Cleveland Clinic, accessed August 12, 2025, https://my.clevelandclinic.org/health/diseases/25207-lithium-toxicity
51. Side effects of lithium - NHS, accessed August 12, 2025, https://www.nhs.uk/medicines/lithium/side-effects-of-lithium/
52. Lithium (Lithobid, Eskalith, and others): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 12, 2025, https://www.webmd.com/drugs/2/drug-5887-795/lithium-carbonate-oral/lithium-controlled-release-oral/details
53. The 9 Lithium Side Effects You May Experience - GoodRx, accessed August 12, 2025, https://www.goodrx.com/lithium/what-lithium-side-effects-should-you-expect
54. Lithium Carbonate ER Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 12, 2025, https://www.drugs.com/sfx/lithium-carbonate-er-side-effects.html
55. Lithium | National Alliance on Mental Illness (NAMI), accessed August 12, 2025, https://www.nami.org/about-mental-illness/treatments/mental-health-medications/types-of-medication/lithium/
56. Lithium Carbonate ER Disease Interactions - Drugs.com, accessed August 12, 2025, https://www.drugs.com/disease-interactions/lithium,lithium-carbonate-er.html
57. Lithium (oral route) - Side effects & dosage - Mayo Clinic, accessed August 12, 2025, https://www.mayoclinic.org/drugs-supplements/lithium-oral-route/description/drg-20064603
58. Extracorporeal Treatment for Lithium Poisoning: Systematic Review ..., accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4422246/
59. Lithium Interactions Checker - Drugs.com, accessed August 12, 2025, https://www.drugs.com/drug-interactions/lithium.html
60. Lithium Carbonate ER Interactions - Drugs.com, accessed August 12, 2025, https://www.drugs.com/drug-interactions/lithium,lithium-carbonate-er.html
61. Drug Interactions with Lithium and Therapeutic Drug Monitoring - Medsafe, accessed August 12, 2025, https://www.medsafe.govt.nz/profs/PUArticles/September2017/Lithium.htm
62. Lithium as medicine (drug interactions) | EBSCO Research Starters, accessed August 12, 2025, https://www.ebsco.com/research-starters/complementary-and-alternative-medicine/lithium-medicine-drug-interactions
63. Taking lithium with other medicines and herbal supplements - NHS, accessed August 12, 2025, https://www.nhs.uk/medicines/lithium/taking-lithium-with-other-medicines-and-herbal-supplements/
64. Could Lithium Explain — and Treat — Alzheimer's Disease ..., accessed August 12, 2025, https://hms.harvard.edu/news/could-lithium-explain-treat-alzheimers-disease
65. Could lithium explain — and treat — Alzheimer's? - Harvard Gazette, accessed August 12, 2025, https://news.harvard.edu/gazette/story/2025/08/could-lithium-explain-and-treat-alzheimers/
66. Study Results | Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder | ClinicalTrials.gov, accessed August 12, 2025, https://clinicaltrials.gov/study/NCT00667745?id=%22NCT00305370%22OR%22NCT00261443%22OR%22NCT00845988%22OR%22NCT00194038%22OR%22NCT00223496%22OR%22NCT00277212%22OR%22NCT00181779%22OR%22NCT00545675%22OR%22NCT00484471%22OR%22NCT00667745%22OR%22NCT03408873%22OR%22NCT00545142%22&rank=3&tab=results
67. Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder | ClinicalTrials.gov, accessed August 12, 2025, https://clinicaltrials.gov/study/NCT03336918
68. Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder | Clinical Research Trial Listing - CenterWatch, accessed August 12, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT03336918/lithium-effects-on-the-brains-functional-and-structural-connectome-in-the-treatment-of-bipolar-disorder
69. Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder - Amit Anand - Grantome, accessed August 12, 2025, https://grantome.com/grant/NIH/R01-MH113256-02
70. Brain structural connectome changes after lithium and quetiapine treatment - Consensus, accessed August 12, 2025, https://consensus.app/search/brain-structural-connectome-changes-after-lithium-/e5pneVObRNmMf0AD-Vmwag/
71. Are Structural Changes Induced by Lithium in the HIV Brain Accompanied by Changes in Functional Connectivity? | PLOS One - Research journals, accessed August 12, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139118